Lucid, Inc.の将来のP / EはN/Aです。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States. The company provides VivaScope 1500, a reflectance confocal imaging system that enables clinicians and researchers to capture confocal images that depict cellular structures of living tissue; and VivaScope 3000, a hand-held in vivo reflectance confocal microscope for skin imaging. It also offers VivaScan software to schedule patients for examinations, perform imaging examinations on one or more lesions during a visit, review, and report on images obtained during an examination, as well as VivaNet, a digital telepathology system. The company was formerly known as Lucid, Inc. and changed its name to Caliber Imaging & Diagnostics, Inc. in August 2012. Caliber Imaging & Diagnostics, Inc. was founded in 1991 and is headquartered in Andover, Massachusetts.